ImmuPharma Soars On Avion Lupus Deal
Validates Management Faith In Lupuzor
US speciality drugs group will fund the $25m costs of the UK company's new Phase III trial of Lupuzor, which has been much maligned by analysts.
You may also be interested in...
Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.
The German major is investing heavily in cancer R&D and has opened the doors of a new facility in the biotech epicenter on the east coast of the US.
The selection of nadulonimab by the Pancreatic Cancer Action Network for its adaptive clinical trial is a strong validation of the Stockholm-based firm's compound, which is also being evaluated for lung cancer.